hydroxychloroquine has been researched along with Connective Tissue Diseases in 27 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Considering the very limited while varying information about the excretion of hydroxychloroquine (HCQ) into human milk, we sought to determine the breast milk concentrations of HCQ in Chinese lactating patients with connective tissue diseases to assess the safety of HCQ in infants of this population." | 9.30 | Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases. ( Du, X; Fu, Q; Liu, R; Mei, D; Peng, W; Zhang, L, 2019) |
| "Several case reports have highlighted symptomatic hypoglycemia as a serious but uncommon adverse effect of hydroxychloroquine (HCQ) in nondiabetic subjects." | 7.96 | Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. ( Dai, Y; Lin, G; Shi, D, 2020) |
| "We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 7.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| "The antimalarial agents chloroquine (CQ) and hydroxychloroquine (HCQ) are used in long-term treatment of connective tissue diseases (CTDs)." | 7.74 | Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. ( Amoura, Z; Costedoat-Chalumeau, N; Funck-Brentano, C; Hulot, JS; Lechat, P; Leroux, G; Piette, JC, 2007) |
| "Hydroxychloroquine has attracted attention in the treatment of COVID-19." | 5.62 | Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. ( Abusoglu, G; Abusoglu, S; Eryavuz Onmaz, D; Onmaz, M; Tezcan, D; Unlu, A; Yerlikaya, FH; Yilmaz, S, 2021) |
| "Several case reports have highlighted symptomatic hypoglycemia as a serious but uncommon adverse effect of hydroxychloroquine (HCQ) in nondiabetic subjects." | 3.96 | Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. ( Dai, Y; Lin, G; Shi, D, 2020) |
| "Patients who used hydroxychloroquine continuously for at least 2 years for various connective tissue diseases were included in the study." | 3.91 | Evaluation of Maculopathy in Patients Using Hydroxychloroquine ( Aslanova, M; Cebeci, Z; Kır Mercül, N; Uğurlu, A, 2019) |
| "Hydroxychloroquine therapy during pregnancy is thought to be safe for foetuses." | 3.75 | Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. ( Flores-Guevara, R; Gold, F; Renaud, C; Renault, F; Richard, P; Vermersch, AI, 2009) |
| "We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 3.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| "The antimalarial agents chloroquine (CQ) and hydroxychloroquine (HCQ) are used in long-term treatment of connective tissue diseases (CTDs)." | 3.74 | Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. ( Amoura, Z; Costedoat-Chalumeau, N; Funck-Brentano, C; Hulot, JS; Lechat, P; Leroux, G; Piette, JC, 2007) |
| " hydroxychloroquine and/or prednisone) were continued during pregnancy." | 3.73 | [Perinatal consequences of maternal connective tissue diseases: a prospective study of 73 cases]. ( Costedoat-Chalumeau, N; de Montgolfier, I; Gold, F; Lapillonne, A; Renaud, C; Vautier-Brouzes, D, 2006) |
| "Hydroxychloroquine has demonstrated a survival benefit in patients with systemic lupus erythematosus; some clinicians advocate its use in all such patients." | 2.55 | Hydroxychloroquine retinopathy. ( Downes, SM; Luqmani, R; Sharma, S; Yusuf, IH, 2017) |
| "Hydroxychloroquine has attracted attention in the treatment of COVID-19." | 1.62 | Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. ( Abusoglu, G; Abusoglu, S; Eryavuz Onmaz, D; Onmaz, M; Tezcan, D; Unlu, A; Yerlikaya, FH; Yilmaz, S, 2021) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "Twenty-six out of 93 pregnancies with systemic lupus erythematosus (SLE) experienced flares during pregnancy." | 1.42 | Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study. ( Fei, Y; Hao, D; Li, Y; Liu, Y; Luo, Y; Zhang, L; Zhao, Y, 2015) |
| "She also had developed anasarca two years prior to presentation." | 1.39 | Systemic lupus erythematosus and granulomatous lymphadenopathy. ( Dhakal, AK; Shah, SC; Shakya, A; Shakya, H; Shiva, RK; Shrestha, D, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 5 (18.52) | 29.6817 |
| 2010's | 16 (59.26) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Eryavuz Onmaz, D | 1 |
| Tezcan, D | 1 |
| Abusoglu, S | 1 |
| Yilmaz, S | 1 |
| Yerlikaya, FH | 1 |
| Onmaz, M | 1 |
| Abusoglu, G | 1 |
| Unlu, A | 1 |
| Dai, Y | 1 |
| Lin, G | 1 |
| Shi, D | 1 |
| Pablos, JL | 1 |
| Galindo, M | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Blanco, R | 1 |
| Gonzalez-Gay, MA | 1 |
| Martinez-Lopez, D | 1 |
| Castrejón, I | 1 |
| Alvaro-Gracia, JM | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Fernandez-Nebro, A | 1 |
| Murray, K | 1 |
| Quinn, S | 1 |
| Turk, M | 1 |
| O'Rourke, A | 1 |
| Molloy, E | 1 |
| O'Neill, L | 1 |
| Mongey, AB | 1 |
| Fearon, U | 1 |
| Veale, DJ | 1 |
| Fardet, L | 2 |
| Nazareth, I | 2 |
| Petersen, I | 2 |
| Lee, YH | 1 |
| Uğurlu, A | 1 |
| Aslanova, M | 1 |
| Cebeci, Z | 1 |
| Kır Mercül, N | 1 |
| Peng, W | 1 |
| Liu, R | 1 |
| Zhang, L | 2 |
| Fu, Q | 1 |
| Mei, D | 1 |
| Du, X | 1 |
| Aubry-Rozier, B | 1 |
| Fabreguet, I | 1 |
| Jivrajka, RV | 1 |
| Genead, MA | 1 |
| McAnany, JJ | 1 |
| Chow, CC | 1 |
| Mieler, WF | 1 |
| Bruzzese, V | 1 |
| Zullo, A | 1 |
| Hassan, C | 1 |
| Shrestha, D | 1 |
| Dhakal, AK | 1 |
| Shiva, RK | 1 |
| Shakya, A | 1 |
| Shah, SC | 1 |
| Shakya, H | 1 |
| Luo, Y | 1 |
| Fei, Y | 1 |
| Li, Y | 1 |
| Hao, D | 1 |
| Liu, Y | 1 |
| Zhao, Y | 1 |
| Merino Argumánez, C | 1 |
| Sáez de La Fuente, I | 1 |
| Molina Collado, Z | 1 |
| Suárez Pita, D | 1 |
| Mestre Gómez, B | 1 |
| Sanchez Izquierdo, JA | 1 |
| Yuan, Y | 1 |
| Ma, H | 1 |
| Ye, Z | 1 |
| Jing, W | 1 |
| Jiang, Z | 1 |
| Yusuf, IH | 1 |
| Sharma, S | 1 |
| Luqmani, R | 1 |
| Downes, SM | 1 |
| Puri, PK | 1 |
| Lountzis, NI | 1 |
| Tyler, W | 1 |
| Ferringer, T | 1 |
| Renault, F | 1 |
| Flores-Guevara, R | 1 |
| Renaud, C | 2 |
| Richard, P | 1 |
| Vermersch, AI | 1 |
| Gold, F | 2 |
| Kobak, S | 1 |
| Deveci, H | 1 |
| McCammack, E | 1 |
| Haggstrom, AN | 1 |
| Noaiseh, G | 1 |
| Bhangle, S | 1 |
| Vivino, F | 1 |
| de Montgolfier, I | 1 |
| Vautier-Brouzes, D | 1 |
| Costedoat-Chalumeau, N | 3 |
| Lapillonne, A | 1 |
| Hulot, JS | 2 |
| Amoura, Z | 2 |
| Leroux, G | 2 |
| Lechat, P | 2 |
| Funck-Brentano, C | 1 |
| Piette, JC | 2 |
| Francès, C | 1 |
| Aymard, G | 1 |
| Winkelmann, RK | 1 |
| Padilha-Goncalves, A | 1 |
| Roul-Bouriat, S | 1 |
| Léauté-Labrèze, C | 1 |
| Bobin, P | 1 |
| Tamisier, JM | 1 |
| Vernhes, P | 1 |
| Geniaux, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Connective Tissue Diseases
| Article | Year |
|---|---|
Hydroxychloroquine, a potentially lethal drug.
Topics: Adult; Anisocoria; Coma; Connective Tissue Diseases; Emergencies; Female; Heart Arrest; Humans; Hydr | 2017 |
Hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Connective Tissue Diseases; Diagnostic Techniques, Ophthalmological; Global He | 2017 |
1 trial available for hydroxychloroquine and Connective Tissue Diseases
| Article | Year |
|---|---|
Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases.
Topics: Adult; Asian People; Breast Feeding; Connective Tissue Diseases; Female; Humans; Hydroxychloroquine; | 2019 |
24 other studies available for hydroxychloroquine and Connective Tissue Diseases
| Article | Year |
|---|---|
Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases.
Topics: Adult; Aged; Antimalarials; Chromatography, High Pressure Liquid; Connective Tissue Diseases; COVID- | 2021 |
Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus.
Topics: Adult; Antirheumatic Agents; Blood Glucose; Connective Tissue Diseases; Dizziness; Fatigue; Female; | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude to Health; Biological Products; Chloroq | 2021 |
Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease: a population-based cohort study.
Topics: Alzheimer Disease; Antirheumatic Agents; Chloroquine; Chronic Disease; Connective Tissue Diseases; D | 2019 |
Response to: 'Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease' by Lee.
Topics: Alzheimer Disease; Chloroquine; Cohort Studies; Connective Tissue Diseases; Humans; Hydroxychloroqui | 2019 |
Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease.
Topics: Alzheimer Disease; Chloroquine; Cohort Studies; Connective Tissue Diseases; Humans; Hydroxychloroqui | 2019 |
Evaluation of Maculopathy in Patients Using Hydroxychloroquine
Topics: Adult; Aged; Antirheumatic Agents; Connective Tissue Diseases; Female; Fluorescein Angiography; Foll | 2019 |
[Connective tissue diseases: news in therapy, role of biologics agents].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Connective Tissue Diseases | 2013 |
Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Cohort Studies; Connective Tissue Diseases; | 2013 |
Connective tissue disease following hepatitis B vaccination.
Topics: Adult; Antirheumatic Agents; Connective Tissue Diseases; Female; Glucocorticoids; Hepatitis B Vaccin | 2013 |
Systemic lupus erythematosus and granulomatous lymphadenopathy.
Topics: Antibodies, Antinuclear; Child; Connective Tissue Diseases; Diagnosis, Differential; Disease Progres | 2013 |
Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Connective Tissue | 2015 |
Interferon-stimulated gene 15 expression in systemic lupus erythematosus : Diagnostic value and association with lymphocytopenia.
Topics: Adult; Aged; Anemia; Case-Control Studies; Connective Tissue Diseases; Correlation of Data; Cytokine | 2018 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2008 |
Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero.
Topics: Antirheumatic Agents; Connective Tissue Diseases; Electroretinography; Evoked Potentials, Visual; Fe | 2009 |
Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study.
Topics: Adolescent; Adult; Aged; Antimalarials; Arthritis, Rheumatoid; Chi-Square Distribution; Chloroquine; | 2010 |
Cutaneous manifestations of connective tissue disease.
Topics: Adolescent; Antirheumatic Agents; Connective Tissue Diseases; Glucocorticoids; Humans; Hydroxychloro | 2011 |
Idiopathic mediastinal fibrosis presenting with antiphospholipid antibody syndrome and manifestations suggestive of connective tissue disease.
Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Antirheumatic Agents; Azathioprine; Connecti | 2012 |
[Perinatal consequences of maternal connective tissue diseases: a prospective study of 73 cases].
Topics: Adult; Connective Tissue Diseases; Female; Glucocorticoids; Humans; Hydroxychloroquine; Infant, Newb | 2006 |
Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.
Topics: Adolescent; Adult; Aged; Antimalarials; Antirheumatic Agents; Bundle-Branch Block; Connective Tissue | 2007 |
Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases.
Topics: Adult; Antirheumatic Agents; Chloroquine; Connective Tissue Diseases; Female; Humans; Hydroxychloroq | 2007 |
Connective tissue panniculitis.
Topics: Adipose Tissue; Adolescent; Adult; Antigen-Antibody Reactions; Atrophy; Biopsy; Connective Tissue Di | 1980 |
[Leprosy disclosed by polyarthritis].
Topics: Aged; Antimalarials; Arthritis; Connective Tissue Diseases; Diagnosis, Differential; Female; Glucoco | 1998 |